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Received February 16, 2016; accepted May 13, 2016AbstractBackground: Multigene assays are recommended for hormone receptor-positive invasive breast carcinoma to determine the risk of recurrence,
but they are highly expensive. We investigated the prognostic values of immunohistochemistry (IHC)-based prognostic models as an alternative
to multigene assays.
Methods: The risk categories estimated by the IHC-based prognostic models were correlated to those estimated by the multigene assays in 71
cases and the follow-up results in 642 consecutive cases of HER2 luminal-type early breast cancer. Cut-off values of IHC-based models were
adjusted based on survival outcome to reveal maximum Harrell C index or based on the maximum positive likelihood ratio correlated to
multigene assay.
Results: All investigated IHC-based models could predict the risk of distant recurrence, but their cut-off values required adjustment. Using
distant recurrence-free survival (DRFS) to refine the cut-off values could improve the prognostic values. Adjusting the cut-off values using the
results of multigene assays, the positive predictive values of an estimate of low risk or low recurrence score ( 21) were higher than 90%. On
average, 23% of cases got different results of risk assessment after adjustment. Although cut-off values adjusted by multigene assay were not
identical to those refined by survival, the adjusted values (17.1 and 23.8) and the refined values (17.5 and 24.5) of the best model (Magee Eq. 1)
were close. Among all the evaluated models, Magee equation 2 was the only one without Ki67, and its prognostic values were the lowest. Using
20% as cut-off for Ki67 as suggested by St. Gallen consensus, we could confidently define luminal A cancer.
Conclusion: It is necessary to adjust the cut-off values of IHC-based prognostic models to fit the purpose. If the estimated risk is clearly high or
low, it may be reasonable to omit multigene assays when cost is a consideration.
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The histopathology of invasive breast cancer in women
greatly impacts its management. In addition to traditional
pathological parameters, such as histological type, grade, and
stage, estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2) status
normally determined by immunohistochemistry (IHC) also
play an important role. Current guidelines recommend that
ER, PR and HER2 testing should be performed in all invasivesevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
650 Y.-Y. Chen et al. / Journal of the Chinese Medical Association 79 (2016) 649e655carcinomas of the breast to aid in treatment selection and to
provide prognostic information.1e4
ER, PR, and HER2 testing defines the clinically useful
subtypes of breast cancer, such as luminal, HER2, and triple-
negative. There is still some uncertainty about the optimal
treatment for patients with luminal-type tumors.5 The St.
Gallen International Expert Consensus suggests endocrine
therapy for luminal A-like tumors defined by high receptor,
low proliferation and low tumor burden ( 3 positive nodes
and tumor size  5 cm), and suggests adding cytotoxic
chemotherapy for luminal B-like tumors with any of the
markers indicative of lesser endocrine responsiveness. Multi-
parameter molecular (multigene) test if available is considered
to have the highest efficacy. A low-risk result can support the
omission of cytotoxic chemotherapy despite luminal B-like
phenotype. However, multigene assays are highly expensive
and not covered by the National Health Insurance of Taiwan.
For economic reasons, the use of prognostic models
composed of four immunohistochemical markers (ER, PR,
HER2, and Ki67) and pathological findings, such as IHC4
scores and Magee equations, work similarly to the multigene
assay to provide information for prognostic and clinical
judgments.6e8 Although treatments guided by IHC4 scores are
more likely to be cost effective,9,10 IHC markers require
standardization before widespread use. ER, PR, and HER2 are
the leading breast cancer markers, and have readily available
guideline recommendations for IHC testing.3,4 Ki67 is not
included in the American Society of Clinical Oncology and
National Comprehensive Cancer Network guidelines because
it shows greater variation in measurement and needs larger-
scale analytical and clinical validation,1,2,11 as was found be-
tween the study populations in the original IHC4 report.6 Ki67
levels were on average about two and a half times higher due
to manual readings and the use of the MIB1 antibody; there-
fore the multiplier was changed to four for Ki67 derived from
MIB1 instead of 10 for that derived from the SP6 antibody and
image analysis to make about 20 points of reduction in the
IHC4 score.6 Additionally, the cut-off point for a low Ki67
index changed from 15% (2009), 14% (2011), or 20% (2013)
to 20e29% (2015) in the St. Gallen International Expert
Consensus,5,12e14 which makes it difficult to follow the cut-off
point. Although there are some recommendations from the
International Ki67 in Breast Cancer Working Group,15 con-
troversies continue to exist regarding counting only hot spots
or all slide areas. Validation of local IHC results is needed
before they can be applied to clinical decision making.
This study aimed to correlate the risk estimation derived
from the IHC to those from multigene-expression assays for
external references and correlate with the follow-up result for
clinical validation. The cut-off values for IHC result to define
luminal A tumors were tested.
2. Methods
The study protocol was approved by the Institutional Re-
view Board of Taipei Veterans General Hospital, Taipei,
Taiwan, R.O.C. Clinicopathological information of 642consecutive patients with HER2 luminal-type (ERþ or
PRþ) early breast cancer who underwent surgery at Taipei
Veterans General Hospital from 2010 to 2012 were retrieved
from the medical records for survival analyses and clinical
validation (Table S1). The median follow-up time was
52.7 months and distant recurrences were observed in 34
(5.3%) of cases. The second study cohort included 71 women
with newly diagnosed HER2 luminal-type (ERþ or PRþ)
invasive carcinoma who had available multigene assay results
(21-gene: 30 cases; 70-gene: 41 cases), collected from October
2009 to December 2015 (Table S2). The follow-up time of
these 71 cases was relatively short (median, 31 months; range,
2e76 months). There was neither local nor distant recurrence.
Among the cohort of 71 cases, 29 cases with results of 21-gene
assay and longer follow-up time (median, 57 months) were
included in the first dataset for clinical validation.
The original histopathological slides, including immuno-
histochemical stains for ER (clone 6F11; Leica Biosystems,
Newcastle, UK, 1:100), PR (clone 16; Leica Biosystems,
1:150), HER2 (A0485; Dako, Glostrup, Denmark, 1:900), and
Ki67 (clone MIB-1; Dako, 1:75), were evaluated by authors
YYC and CYH without knowledge of the 21-gene or 70-gene
assay results. The evaluations of ER, PR, and HER2 followed
previously reported instructions.3,4 One percent or more of
tumor cells exhibiting nuclear staining was regarded as posi-
tive for ER and PR.3 HER2 positivity was defined by complete
intense membrane staining in > 10% of tumor cells.4 The
percentages of Ki67 positive tumor cells derived from at least
three high-power fields (400) were averaged for the Ki67
labeling index using manual counting or image analysis
(ImmunoRatio).16,17
Fisher's exact test was used to compare the distributions of
categorical variables. Differences between continuous vari-
ables were compared using the KruskaleWallis test. Distant
recurrence-free survival (DRFS) was measured from the date
of surgery to the date of distant recurrence. Contralateral
disease, other second primary cancers, and death before
distant recurrence were considered censoring events. Locore-
gional recurrences were not considered events or censoring
events. Survival curves were plotted using the KaplaneMeier
method, and their differences were calculated by log-rank test.
Cox regression model was used to evaluate the hazard of
recurrence. The prognostic values were compared using the
Harrell C index, which is a rank parameter that measures the
ordinal predictive power of a survival model by determining
the probability of concordance between the predicted and the
observed survival.18 Harrell C index can range from 0.5 (no
predictive discrimination) to 1.0 (perfect separation of patients
with different outcomes).18 The risk categories estimated by
IHC4,6 Magee equations,8 or St. Gallen Consensus5,14 were
correlated to the multigene assay results. The details of IHC4
scores and Magee equations are listed in the footnotes of
Table 1. The agreement of risk classifications was measured
using kappa statistics, which were calculated as (observed
agreementagreement by chance) divided by (1agreement
by chance). The kappa statistics can range from 1 to þ1,
while the greater values reflect stronger agreement. The
Table 1
The risk groups classified by IHC4 score and Magee equation using original cut-off values.
n (%) 5y-DRFS (%) Univariate a Multivariate b
C HR ( p) C HR ( p)
IHC4 score
Ki67 multiplier 4 c 0.6982 0.7238
<e29.9 307 (47.8) 97.6 0.42 (0.064) 0.47 (0.114)
29.9e29.9 245 (38.2) 93.6 1 (Reference) 1 (Reference)
> 29.9 90 (14.0) 83.1 3.22 (0.002) 2.84 (0.009)
Ki67 multiplier 10 d 0.7148 0.7456
<e29.9 129 (20.1) 99.2 0.21 (0.130) 0.23 (0.160)
29.9e29.9 351 (54.7) 95.5 1 (Reference) 1 (Reference)
>29.9 162 (25.2) 86.9 3.60 (<0.001) 3.16 (0.002)
Magee equation
Magee 1 e 0.7166 0.7464
<18 286 (44.6) 98.5 0.19 (0.002) 0.23 (0.008)
18e30 315 (49.1) 91.9 1 (Reference) 1 (Reference)
31 41 (6.4) 78.9 3.43 (0.003) 3.47 (0.003)
Magee 2 f 0.6417 0.6902
<18 307 (47.8) 97.2 0.35 (0.011) 0.43 (0.045)
18e30 301 (46.9) 91.6 1 (Reference) 1 (Reference)
31 34 (5.3) 87.5 1.90 (0.239) 1.69 (0.351)
Magee 3 g 0.7347 0.7530
<18 335 (52.2) 98.4 0.18 (0.001) 0.21 (0.002)
18e30 270 (42.1) 90.9 1 (Reference) 1 (Reference)
31 37 (5.8) 76.4 3.41 (0.003) 3.29 (0.006)
C¼Harrell C; 5y-DRFS¼ 5-year distant recurrence-free survival rate; ER ¼ estrogen receptor; HER¼ human epidermal growth factor receptor; HR ( p) ¼ hazard
ratio (significance); IHC ¼ immunohistochemistry; PR ¼ progesterone receptor.
a Univariate analyses.
b Multivariate analyses with adjustment of chemotherapy and hormonal therapy.
c IHC4 score ¼ 94.7  [0.1  ER H-score/30  0.079  PR %/10 þ 0.586  HER2 þ 0.24  ln(1 þ 4  Ki67)].
d IHC4 score ¼ 94.7  [0.1  ER H-score/30  0.079  PR %/10 þ 0.586  HER2 þ 0.24  ln(1 þ 10  Ki67)].
e Magee 1 ¼ 15.31385 þ 1.4055  Nottingham score  0.01924  ER H-score  0.02925  PR H-score þ HER2 (0 for negative, 0.77681 for equivocal,
11.58134 for positive) þ 0.78677  tumor size þ 0.13269  Ki67.
f Magee 2 ¼ 18.8042 þ 2.34123  Nottingham score  0.03749  ER H-score  0.03065  PR H-score þ HER2 (0 for negative, 1.82921 for equivocal,
11.51378 for positive) þ 0.04267  tumor size.
g Magee 3 ¼ 24.30812  0.02177  ER H-score  0.02884  PR H-score þ HER2 (0 for negative, 1.46495 for equivocal, 12.75525 for
positive) þ 0.18649  Ki67.
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divided by (1specificity), while the greater LRþ value
indicated an increased probability that the target was present.
Cut-off values of Ki67, IHC4 scores, and Magee equations
were adjusted based on survival outcome to reveal maximum
Harrell C index or based on the maximum positive likelihood
ratio correlated to multigene assay. As cytotoxics may be
added in patients with 21-gene recurrence scores (RS) > 25,14
one case of intermediate risk with RS ¼ 26 was regarded as
high risk. Eight cases of intermediate risk with RS ranging
from 18 to 21 were regarded as low risk in the correlation
analyses. The p-values were derived from two-tailed tests, and
p < 0.05 was considered significant.
3. Results3.1. Correlation of IHC4 scores and Magee equations
with DRFSThe distributions of risk categories of the 642 cases clas-
sified by IHC4 score and Magee equations using their original
cut-off values are listed in Table 1. Although the DRFS of thehigh-risk group either defined by IHC4 scores or Magee Eqs. 1
and 3 was shorter than those of intermediate- and low-risk
groups, the proportion of high-risk groups revealed great dif-
ferences which ranged from 5.8% to 25.2%. Also, the survival
differences between intermediate and low-risk groups were not
significant in IHC4 scores.
The values calculated by IHC4 scores and Magee equations
all showed significant and continuous association with recur-
rence (Table S3). Their prognostic values represented by
Harrell C were not significantly different, except that the
prognostic value of Magee Eq. 2 was inferior to those of
Magee Eqs. 1 and 3 ( p ¼ 0.001 and p ¼ 0.015, respectively).
The prognostic value with adjustment of chemotherapy and
hormonal therapy of Magee Eq. 2 was also inferior to that of
Magee Eq. 1 ( p ¼ 0.013).3.2. The cut-off values of IHC4 scores and Magee
equations refined by DRFSThe cut-off values of IHC4 scores and Magee equations
could be optimized by testing different cut-off values to give
the maximum Harrell C value. Using refined cut-off values,
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All the Harrell C values were increased and the hazard ratios
between intermediate- and low-risk groups classified by IHC4
scores became significant (Table 2). The survival curves
stratified by risk groups showed a similar trend (Figs. S1eS2).
The survival difference between intermediate- and low-risk
groups was not significant in Magee Eq. 2. Its prognostic
value was the lowest and was significantly inferior to those by
Magee Eq. 1 and 3. The proportions of risk categories clas-
sified by different IHC4 scores and Magee equations were
closer. The proportions of high risk ranged from 22.4% to
27.4%, while those of low risk ranged from 35.4% to 43.2%.3.3. Correlation of IHC4 scores and Magee equations
with multigene assaysPR, Ki67, IHC4 scores, and Magee equations were signif-
icantly related to the risk categories derived from multigene
assays, while ER and the other clinicopathological features did
not show a significance. The cut-off values of IHC4 scores and
Magee equations could be adjusted by the maximum positive
likelihood ratio in predicting the low- and high-risk categories
derived from multigene assays (Table 3). Although the 21- and
70-gene assay were two different assays, the adjusted cut-off
values did not change significantly when the 30 cases with
results of the 21-gene assay were excluded. The cut-off values
in predicting the high-risk category became slightly lower,
while those in predicting the low-risk category were the same
(Table S4). The positive predictive values of an estimate of
low risk or low recurrent score ( 21) were higher than 90%.Table 2
The risk groups classified by IHC4 score and Magee equation using optimized cu
n (%) 5y-DRFS (%)
IHC4 score
Ki67 multiplier 4
e40.1 227 (35.4) 99.0
40.0e13.8 270 (42.1) 94.5
13.9 145 (22.6) 85.3
Ki67 multiplier 10
e19.4 227 (35.4) 99.0
19.3e34.5 270 (42.1) 94.5
34.6 145 (22.6) 85.3
Magee equation
Magee 1
17.5 277 (43.2) 99.2
17.6e24.4 221 (34.4) 94.5
24.5 144 (22.4) 83.5
Magee 2
13.9 229 (35.7) 98.1
14.0e22.3 237 (36.9) 94.3
22.4 176 (27.4) 88.5
Magee 3
17.0 277 (43.2) 98.8
17.1e21.8 192 (29.9) 94.3
21.9 173 (27.0) 86.3
C¼Harrell C; 5y-DRFS ¼ 5-year distant recurrence-free survival rate; HR ( p) ¼
a Univariate analyses.
b Multivariate analyses with adjustment of chemotherapy and hormonal therapy.The multigene adjusted cut-off values were lower than the
original ones in most of the models, except for IHC4 score
using a Ki67 multiplier of 10. Applying the adjusted cut-off
values to the cohort of 642 cases (Table 4), on average, 24%
were reclassified into a different category. Magee Eq. 1
showed the maximum prognostic value (Harrell C) and clas-
sified the fewest individuals (31.3%) into the intermediate-risk
group. Among models, the proportions of high-risk groups
were relatively close (range, 20.9e29.0%) and the survival
curves revealed a similar trend (Figs. S1eS2). Of note, the
survival differences between low- and intermediate-risk
groups were mostly insignificant in multivariate analyses
with chemotherapy and hormonal therapy adjustment.
Although the cut-off values adjusted by multigene assay
(Table 4) were not identical to those refined by survival (Table
2), cut-off values of Magee Eq. 1 optimized by different
methods were close (17.1 and 23.8 vs. 17.5 and 24.5,
respectively). These optimized cut-off values were lower than
the original values (18 and 31). Additionally, 27.4% and
17.5% of cases were upgraded to a higher risk category than
the original one.3.4. Cut-off value for Ki67 index to define luminal A
tumorsWe tested the criteria of St. Gallen consensus using
different Ki67 values to define luminal A tumors, and found
that using 20% as cut-off got the maximum positive likelihood
ratio (Table S5). However, using median (25%) as a cut-off
point showed the highest concordance (67.6%) with thet-off values for survival.
Univariate a Multivariate b
C HR ( p) C HR ( p)
0.7481 0.7714
0.20 (0.032) 0.22 (0.047)
1 (Reference) 1 (Reference)
3.38 (0.001) 3.10 (0.003)
0.7481 0.7714
0.20 (0.032) 0.22 (0.047)
1 (Reference) 1 (Reference)
3.38 (0.001) 3.10 (0.003)
0.7812 0.7841
0.16 (0.016) 0.17 (0.024)
1 (Reference) 1 (Reference)
3.71 (0.001) 3.58 (0.001)
0.6916 0.7250
0.37 (0.091) 0.44 (0.157)
1 (Reference) 1 (Reference)
2.46 (0.018) 2.25 (0.034)
0.7481 0.7733
0.23 (0.026) 0.25 (0.036)
1 (Reference) 1 (Reference)
2.93 (0.007) 2.67 (0.016)
hazard ratio (significance); IHC ¼ immunohistochemistry.
Table 3
Cut-off values adjusted by the maximum positive likelihood ratio in predicting
the risk categories derived from multigene assays.
n Low Intermediate a High LRþ b Kappa c
Total 71 42 (59) 9 (13) d 20 (28)
IHC4 score
Ki67
multiplier 4
e43.6 24 21 (88) 2 (8) 1 (4) 9.7
43.5e8.5 37 21 (57) 6 (16) d 10 (27)
8.6 10 0 (0) 1 (10) 9 (90) 21.4 0.482
Ki67
multiplier 10
e22.9 24 21 (88) 2 (8) 1 (4) 9.7
22.8e29.1 37 21 (57) 6 (16) d 10 (27)
29.2 10 0 (0) 1 (10) 9 (90) 21.4 0.482
Magee equation
Magee 1
17.1 30 25 (83) 4 (13) 1 (3) 12.2 0.417
17.2e23.7 33 17 (52) 4 (12) d 12 (36)
23.8 8 0 (0) 1 (13) 7 (88) 16.7
Magee 2
15.5 25 21 (84) 3 (12) 1 (4) 10.1 0.321
15.6e24.5 42 21 (50) 5 (12) d 16 (38)
24.6 4 0 (0) 1 (25) 3 (75) 7.1
Magee 3
16.2 25 22 (88) 2 (8) 1 (4) 10.1
16.3e23.2 37 20 (54) 6 (16) d 11 (30)
23.3 9 0 (0) 1 (11) 8 (89) 19.0 0.433
Data are presented as n (%).
IHC ¼ immunohistochemistry; LRþ ¼ positive likelihood ratio;
RS ¼ recurrence scores.
a Eight cases with 21-gene RS < 25 (range, 18e21) were regarded as low
risk, and one case with RS  25 was regarded as high risk in the analyses.
b Positive likelihood ratio in predicting the low- or high-risk group.
c Kappa statistics of two-tier risk estimation using the cut-off value.
d Including one case with RS ¼ 26.
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value than by using 14% or 20% (both p < 0.001) in the cohort
of 642 cases (Table S6).
4. Discussion
In this study, we confirmed that IHC-based prognostic
models provided inexpensive risk assessments, but their cut-
off values required adjustment. On average, 23% of cases
got different results of risk assessment after adjustment. The
cut-off values refined by survival outcomes could get better
prognostic values and predict more differences in survival
among the risk groups. However, the cut-off values refined by
survival did not match with those correlated to multigene as-
says. Magee Eq. 1was the best of the prognostic models
evaluated. It had the highest prognostic values with regard to
the value calculated by the equation (Table S3) and the risk
categories classified by the adjusted cut-off values (Table 2
and Table 4, respectively). Also, its cut-off values refined by
survival (17.5 and 24.5, respectively) were very close to those
adjusted by multigene assays (17.1 and 23.8, respectively).
Replacing the cut-off of Ki67 (20%) by the median (25%) of
Ki67 for our cases got higher prognostic values and betterconcordance with multigene assay in distinguishing the low-
risk from the high-risk luminal-type cancers, but the positive
likelihood ratio of predicting the low-risk group decreased.
It is debatable, however, to include Ki67 to distinguish the
low-risk from the high-risk luminal-type cancers.5 In our
study, Ki67 was significantly related to the DRFS and the risk
categories derived from multigene assays. The studied IHC-
based prognostic models all showed prognostic significance.
Magee Eq. 2 was the only one not including Ki67 in the
equation, and its prognostic values were the lowest and
significantly inferior to those of the other Magee equations.
These findings support the theory that Ki67 scores carry
important prognostic information. Although defining a single
useful cut-off point may not be fully applicable to all condi-
tions and laboratories, using a higher Ki67 index
(Ki67  35%) to indicate a poor prognosis (Table S1) and a
lower Ki67 index (Ki67 < 20%) to confidently define luminal
A cancer is feasible in our institute.
When the IHC-based prognostic models are used as prog-
nostic markers, the DRFS corrected cut-off values should be
the most appropriate. If the aim is to predict benefit from
chemotherapy, using the result of multigene assays for
external references should be a successful method. Although a
threshold value has not been established, multigene assays are
frequently used to assist in decisions about the inclusion of
cytotoxic chemotherapy. The optimal threshold of multigene
assays to define the clinical benefit should be based on the
thresholds that are clinically validated against the outcomes
compared between treated and untreated patients. The 21-gene
assay has been shown to predict chemotherapy benefit in two
analyses in Phase III clinical trial settings.19,20 The low-risk
group (RS < 18) did not appear to benefit from chemo-
therapy, and the high-risk group (RS > 30) derived major
benefit from chemotherapy. The benefit in the intermediate
group was unclear. Another two randomized clinical trials
(TAILORx and RxPONDER trials) are currently being con-
ducted to evaluate the benefit of chemotherapy in patients with
low to intermediate risk (RS < 25). The 70-gene assay has also
been reported as being predictive of chemotherapy benefit
based on the results of pooled study series, and its prospective
validation in a randomized clinical trial (the MINDACT trial)
is ongoing.21
Whether the multigene assay is more accurate or offers
more information than basic IHC is controversial.22,23 The
expensive multigene assays push us to refine the risk stratifi-
cation for adjuvant chemotherapy for patients with hormonal
receptor-positive tumors, but there is insufficient evidence to
support that these assays play a role in determining ER, PR, or
HER2 status in unselected patients.2e4,24 ER, PR, and HER2
status determined by IHC are necessary for breast cancer pa-
tients. Using basic IHC for risk stratification has advantages in
its low cost and ready availability. However, the potential for
interlaboratory variation in the values of IHC remains a
justifiable concern. Efforts to improve standardization and
reproducibility of IHC are needed. In fact, the results of
multigene assays for the same cohort of breast cancer patients
can be discordant,25 and agreement between the assays in one
Table 4
The risk groups classified by IHC4 score and Magee equation using cut-off values validated by multigene assays.
n (%) 5y-DRFS (%) Univariate a Multivariate b
C HR ( p) C HR ( p)
IHC4 score
Ki67 multiplier 4 0.7296 0.7579
e43.6 180 (28.0) 99.4 0.13 (0.046) 0.14 (0.062)
43.5e8.5 298 (46.4) 94.8 1 (Reference) 1 (Reference)
8.6 164 (25.6) 87.1 3.02 (0.002) 2.74 (0.006)
Ki67 multiplier 10 0.7303 0.7584
e22.9 180 (28.0) 99.4 0.13 (0.046) 0.14 (0.062)
22.8e29.1 299 (46.6) 94.8 1 (Reference) 1 (Reference)
29.2 163 (25.4) 87.0 3.05 (0.002) 2.76 (0.006)
Magee equation
Magee 1 0.7537 0.7676
17.1 255 (39.7) 99.1 0.17 (0.025) 0.20 (0.039)
17.2e23.7 201 (31.3) 94.6 1 (Reference) 1 (Reference)
23.8 186 (29.0) 86.6 3.03 (0.005) 2.84 (0.010)
Magee 2 0.6793 0.7080
15.5 197 (30.7) 97.8 0.45 (0.154) 0.53 (0.265)
15.6e24.5 331 (51.6) 94.7 1 (Reference) 1 (Reference)
24.6 114 (17.8) 85.7 3.14 (0.002) 2.78 (0.006)
Magee 3 0.7324 0.7523
16.2 223 (34.7) 99.0 0.18 (0.023) 0.20 (0.034)
16.3e23.2 285 (44.4) 94.3 1 (Reference) 1 (Reference)
23.3 134 (20.9) 85.5 2.95 (0.002) 2.67 (0.008)
C¼Harrell C; 5y-DRFS ¼ 5-year distant recurrence-free survival rate; HR ( p) ¼ hazard ratio (significance); IHC ¼ immunohistochemistry.
a Univariate analyses.
b Multivariate analyses with adjustment of chemotherapy and hormonal therapy.
654 Y.-Y. Chen et al. / Journal of the Chinese Medical Association 79 (2016) 649e655study was only moderate (Kappa ¼ 0.527).23 In the present
study, IHC4 scores and Magee equations using the cut-off
values with maximum positive likelihood ratio reached fair
to moderate agreement with those using multigene assays
(Kappa ¼ 0.390e0.470; Table 3). As a matter of fact, we
could not expect totally matched results since the principles
and the targets of detection by the IHC and multigene assays
were different. At least the use of IHC can reduce the number
of cases requiring expensive multigene assays. If the risk
estimated by Magee Eq. 1 falls clearly in the high- or low-risk
category, a dramatically different result from multigene assays
should not be expected.
The current study was limited by data collected in a single
institute with restricted sample size and follow-up time.
Despite this, the 5-year DRFS rate of our cases (5.3%) is
consistent with those in the literature (4e5%).6,7 Our survival
refined cut-off values were close to those adjusted by multi-
gene assays (external reference). Further validations in larger
cohorts with a longer follow-up time and in different labora-
tories are needed for IHC-based prognostic models to be
widely implemented.
In conclusion, it is necessary to adjust the cut-off values of
IHC-based prognostic models to fit the purpose. The risk
group was reclassified in about one fifth of our cases after
adjustment. If the estimated risk from the IHC-based models is
clearly high or low, the result from the multigene assays is less
likely to be significantly different, and it may be reasonable to
omit multigene assays in this setting when cost is a
consideration.Acknowledgments
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